• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

By: Autolus Therapeutics plc via GlobeNewswire
April 22, 2025 at 07:00 AM EDT

LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025.

Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com

Contact:  

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

Olivia Manser 
+44 7780 471 568 
o.manser@autolus.com 


Primary Logo

More News

View More
3 Stocks Flying Under the S&P 500 Radar
Today 17:11 EDT
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
Tickers AAPL AEVA AMD GOOGL
Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing
Today 17:08 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AWEVF QCOM
3 Cloud Build-Out Stocks Behind the AI Infrastructure Boom
Today 16:39 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN ANET META MSFT
ServiceNow: The 2nd Wave of AI Spending Is Here
Today 13:20 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers NOW
Tractor Supply Revs Up on Forecast Hike and Bullish Signals
Today 12:10 EDT
Via MarketBeat
Tickers TSCO
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap